Could Alternative Medicine Contribute to the Future of Drug Development?

The Historical Context of Essential Oils

Essential oils, including lavender and peppermint oil, have been utilized for their therapeutic benefits for centuries. However, as modern medicine evolved, these oils transitioned from primary treatments to being categorized as alternative or complementary medicine.

Recent Research on Essential Oil Components

A recent study published in *Nature* investigates whether the components found in essential oils could serve as unexplored pharmacological resources. The research focuses on the current drug development process and aims to evaluate the potential of essential oils in this field.

Challenges in Drug Development

Pharmaceutical companies face the challenge of processing numerous compounds to identify viable drug candidates. To streamline this process, they employ Drug Discovery Filters (DDFs), which consist of tests to determine if a molecule possesses the necessary physical and chemical properties to be considered medicinal. These properties are known as Drug Discovery Parameters (DDPs).

Examining Essential Oil Components

The study investigates essential oil components (EOCs) and their DDPs to assess the validity of their exclusion from the drug discovery process. Researchers compared the DDPs of commercially available essential oil components against a series of DDFs and also compared these results with existing drug compounds.

Study Findings

The research examined 175 essential oils, identifying 6,142 components, which were narrowed down to 627 unique components after duplicates were removed. The components were evaluated based on four key qualities: bioavailability, lead-likeness, fragment-based drug discovery, and drug-likeness.

Bioavailability Results

All 627 components successfully passed the drug discovery filters for bioavailability, with 94% of individual components meeting this criterion. This indicates that essential oil components can effectively enter circulation in the bloodstream upon introduction into the human body.

Lead-likeness and Fragment-based Drug Discovery

In terms of lead-likeness, which assesses fat solubility and molecular mass, most essential oil components performed well. However, only 32% passed all five criteria for fragment-based drug discovery, which identifies pieces of molecules likely to bind to biological targets.

Drug-likeness Evaluation

The assessment of drug-likeness involved comparing the chemical structures of essential oil components to established drug compounds. Encouragingly, 60% of these components passed the related DDF.

Overall Performance of Essential Oil Components

Out of 627 essential oil components, only nine did not pass any variant of the DDFs, while eight passed every variant. Approximately 94% of the tested components met at least four out of six DDFs, a figure that surpasses the two-thirds of approved drugs achieving the same standard. However, it is important to note that six times more approved drugs passed all DDFs compared to essential oil components.

Conclusion and Future Directions

The findings are promising, revealing that essential oils could represent a largely overlooked source for drug development. While the study alleviated concerns regarding the physical and chemical properties of these oils, numerous challenges remain in the drug development process. Further research is needed to integrate more essential oil components into pharmacological applications.

Reference

Feyaerts AF, Luyten W, Van Dijck P. Striking essential oil: tapping into a largely unexplored source for drug discovery. Sci Rep. 2020;10(1):2867.